Entheon Biomedical Corp

Company Profile

Entheon Biomedical Corp had its IPO on under the ticker symbol ENTBF.

The company operates in the Healthcare sector and Biotechnology industry. Entheon Biomedical Corp has a staff strength of 2 employees.

Stock update

Shares of Entheon Biomedical Corp opened at $0.02 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.02 - $0.02, and closed at $0.02.

This is a +5.29% increase from the previous day's closing price.

A total volume of 250 shares were traded at the close of the day’s session.

In the last one week, shares of Entheon Biomedical Corp have increased by +11.88%.

Entheon Biomedical Corp's Key Ratios

Entheon Biomedical Corp has a market cap of $1.19 million, indicating a price to book ratio of 0.2195 and a price to sales ratio of 9.5966.

In the last 12-months Entheon Biomedical Corp’s revenue was $309677 with a gross profit of $189677 and an EBITDA of $-3542866. The EBITDA ratio measures Entheon Biomedical Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Entheon Biomedical Corp’s operating margin was -706.07% while its return on assets stood at -30.39% with a return of equity of -15.59%.

In Q4, Entheon Biomedical Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1248.2%.

Entheon Biomedical Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Entheon Biomedical Corp’s profitability.

Entheon Biomedical Corp stock is trading at a EV to sales ratio of 10.6686 and a EV to EBITDA ratio of -0.1939. Its price to sales ratio in the trailing 12-months stood at 9.5966.

Entheon Biomedical Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$671214.00

Total Liabilities

$150733.00

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Entheon Biomedical Corp ended 2025 with $671214.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $671214.00 while shareholder equity stood at $520481.00.

Entheon Biomedical Corp ended 2025 with $0 in deferred long-term liabilities, $150733.00 in other current liabilities, in common stock, $-20679416.00 in retained earnings and $0 in goodwill. Its cash balance stood at $490913.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Entheon Biomedical Corp’s total current assets stands at $646214.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $150733.00 and inventory worth $13811.00.

In 2025, Entheon Biomedical Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Entheon Biomedical Corp paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$0.02

52-Week High

$0.081

52-Week Low

$0.01

Analyst Target Price

$

Entheon Biomedical Corp stock is currently trading at $0.02 per share. It touched a 52-week high of $0.081 and a 52-week low of $0.081. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.02 and 200-day moving average was $0.02 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 863.1% of the company’s stock are held by insiders while 0% are held by institutions.